Investing.com - Merck&Co (NYSE: MRK) reported second quarter EPS of $2.28, $0.12 better than the analyst estimate of $2.16. Revenue for the quarter came in at $16.11B versus the consensus estimate of $15.85B.
Guidance
Merck&Co sees FY 2024 EPS of $7.94-$8.04 versus the analyst consensus of $8.16.
Merck&Co sees FY 2024 revenue of $63.40B-$64.40B versus the analyst consensus of $64.30B.
Merck&Co's stock price closed at $127.78. It is down -0.37% in the last 3 months and up 19.81% in the last 12 months.
Merck&Co saw 7 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Merck&Co's stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co's Financial Health score is "great performance".
Check out Merck&Co's recent earnings performance, and Merck&Co's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar